Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Tesamorelin and Tirzepatide have evidence — compare verdict strength side-by-side.
Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base.
any
Egrifta / Egrifta SV (prescription, via a clinician)
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
26-52 weeks
6-12 months
Within months of stopping
20-24 weeks
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
J Clin Endocrinol Metab (2010) · Rct · n=806
Pooled analysis of two multicenter, double-blind, placebo-controlled phase-3 RCTs (n=806 ART-treated HIV patients with excess abdominal fat), randomized 2:1 to tesamorelin 2 mg or placebo subcutaneously daily
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
J Acquir Immune Defic Syndr (2010) · Rct · n=404
12-month phase-3 RCT in 404 ART-treated HIV patients with excess abdominal fat; randomized 2:1 to tesamorelin 2 mg sc daily or placebo, then rerandomized at 6 months
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
AIDS (2008) · Rct · n=410
26-week safety-extension RCT (n=410) of the phase-3 program; tesamorelin 2 mg vs placebo subcutaneously daily, with rerandomization at week 26
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Tirzepatide has a higher evidence score (7.8/10 vs 5/10) and wins in 2 of 3 categories.
No known interactions between Tesamorelin and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.